PIK3CA and vascular malformation: The mTOR inhibitor sirolimus may also be worth studying in view of the established interaction and coregulation of PIK3CA/AKT/mTOR with the MAPK/MEK/Ras pathway, as well as its successful usage in treating complex vascular malformations [32, 40, 41].